Please login to the form below

Not currently logged in

Lilly's Alimta patent confirmed

A US District Court has confirmed the validity of Eli Lilly's patent for Alimta – a drug used in chemotherapy

The US District Court for the District of Delaware has confirmed the validity of Eli Lilly's patent for Alimta (pemetrexed) – a drug used in chemotherapy.

In the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc, the court ruled that Lilly's patent provide protection for Alimta in the US until July 2016. The case followed Teva's abbreviated new drug application (ANDA) to manufacture a generic version of Alimta.

Alimta, used in the treatment of malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC), achieved global sales of $1.64bn over the first three quarters of 2010.

"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A Armitage, senior vice president and general counsel for Lilly. "We continue to emphasise that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve.

"These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

16th November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....